Sutro Biopharma (STRO)

• Market cap: $133M
• 1 day: -6.08%
• 5 days: -2.01%
• 1 month: 40.63%
• 3 months: 40.63%
• 6 months: 82.79%
• Year to date: 42.43%
• 1 year: -17.84%
• 5 years: -93%
• 10 years: -89.73%
• Sector: Healthcare
• Industry: Biotechnology

About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Employees: 131